Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here. More than half of patients with psoriatic arthritis ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Early initiation of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE) reduces the risk for progression to systemic lupus erythematosus (SLE) by 87% over time.

and cutaneous lupus erythematosus, which affects the skin and has a broad spectrum of clinical manifestations. The treatment of SLE is highly individualized and physicians (mainly rheumatologists ...

Extra-cutaneous symptoms that suggest systemic ... The patient is a 47-year-old male with a 6-year history of systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome.

The foregoing results lead to the conclusion that patients with disseminated lupus erythematosus and some patients with rheumatoid arthritis present a delayed cutaneous hypersensitivity when ...

Of note are the derivation of the term lupus and the clinical descriptions of the cutaneous lesions of lupus vulgaris ... The first published illustrations of lupus erythematosus were included in von ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment. Cutaneous lupus erythematosus is a common manifestation ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...